/Companies

Cambridge Cancer Genomics

DefunctYC S17

Cambridge, GB · Founded 2015 · 25 employees · 16 known investors

Find your way into Cambridge Cancer Genomics

Sign up to see every warm intro you have to Cambridge Cancer Genomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cambridge Cancer Genomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

CCG.ai develops software for data-driven precision oncology, using clinical and genomic data to identify biomarkers of treatment response and help oncologists choose cancer therapies. It serves clinicians and oncologists in the cancer treatment field.

Founders & leadership· Y Combinator alumni (S17)

Cambridge Cancer Genomics was founded in 2015 by John Cassidy, Nirmesh Patel, and Evaline Tsai.

JCJohn Cassidy
John CassidyCEOInvestor at Kindred Capital
NPNirmesh Patel
Nirmesh PatelChief Scientific OfficerNirmesh Patel is founder and Chief Scientific Officer of Cambridge Cancer Genomics, which develops software using clinical and genomic data to help oncologists select cancer treatments tailored to individual patients.
ETEvaline Tsai
Evaline TsaiCPO
JT
Joan TanousOperations Associate
HC
Harry CliffordCTO2017–2021
LH
Luke HarriesMachine Learning Engineer (Contracting and Internship)2018–2018

Investors · 16

Pi Campuslisted by Pi CampusRome · $55K – $540K

How we know: Y Combinator's founder network · Not right? Tell us

Endure CapitalreportedAmsterdam

How we know: Y Combinator's founder network · Not right? Tell us

FrialereportedNashville · $100K – $600K

How we know: Y Combinator's founder network · Not right? Tell us

Hack VCreportedPalo Alto · $3M

How we know: Y Combinator's founder network · Not right? Tell us

MetaplanetreportedTallinn · $500K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

Refactor CapitalreportedBurlingame · $1M – $2M

How we know: Y Combinator's founder network · Not right? Tell us

Romulus CapitalreportedBoston · $250K – $10M

How we know: Y Combinator's founder network · Not right? Tell us

RTLP LLCreportedNew York

How we know: Y Combinator's founder network · Not right? Tell us

Vy CapitalreportedLondon

How we know: Y Combinator's founder network · Not right? Tell us

Related companies · 5

GamgeeGAMGEE develops personalised mRNA cancer vaccines for dogs, created from the animal's own tumour tissue to help its immune system fight the cancer. The company manages the full process end to end—from diagnosis and tissue sampling with the pet owner's vet, to genomic analysis and treatment delivery via veterinary oncologists—and is currently running clinical trials in Australia while accepting applications globally.
Notable LabsNotable Labs operates a personalized drug discovery platform that tests combinations of FDA-approved drugs against a patient's own cancer cells to identify treatment options, focusing initially on relapsed and refractory blood cancer. It runs a highly automated lab with custom software and works with relapsed/refractory cancer patients as well as pharma and biotech partners.
Numerion LabsNumerion Labs develops machine learning algorithms for drug discovery, combining computational chemistry, structural biology, and medicinal chemistry. It builds AI-driven platforms aimed at accelerating the identification of new medicines.
FidoCureFidoCure provides precision medicine for canine oncology, offering genetic sequencing and targeted therapies that enable veterinarians to treat dogs with cancer. It operates a US network of veterinary clinics and oncologists for both cancer diagnostics and treatment.
Clear GeneClear Gene develops diagnostic tests used in cancer care that indicate to doctors whether a tumor has been fully removed. The company operates in the oncology and women's health diagnostics space.

Companies working in the same space as Cambridge Cancer Genomics.

Legal entities · 1

corporate structure
Cambridge Cancer Genomics, Inc.

Frequently asked questions

What does Cambridge Cancer Genomics do?
CCG.ai develops software for data-driven precision oncology, using clinical and genomic data to identify biomarkers of treatment response and help oncologists choose cancer therapies. It serves clinicians and oncologists in the cancer treatment field.
Who founded Cambridge Cancer Genomics?
Cambridge Cancer Genomics was founded by John Cassidy, Nirmesh Patel, Evaline Tsai in 2015.
Who are Cambridge Cancer Genomics's investors?
Cambridge Cancer Genomics's investors include Amplify Partners, Funders Club Management, FundersClub, Pi Campus, Soma Capital, Y Combinator, AME Cloud Ventures, Endure Capital and 8 more.
Where is Cambridge Cancer Genomics headquartered?
Cambridge Cancer Genomics is headquartered in Cambridge, GB.